Please login to the form below

Not currently logged in
Email:
Password:

Takeda names Marc Princen as president of EUCAN

He previously served as a president at Merck

Takeda has appointed Marc Princen as corporate officer and president of the EUCAN (Europe and Canada) business unit.

In his new role, Princen will lead all business operations in Europe and Canada and will directly report to Christophe Weber, president and chief operating officer at Takeda.

Concerning the new appointment, Weber said: “I am fully confident that Marc, with his rich set of skills and expertise both broadly across the pharmaceutical industry and specifically in a majority of Takeda's therapeutic areas, will prove a great asset for Takeda.

“His passion for healthcare and commitment to improving lives are in alignment with Takeda's mission and core values of Takeda-ism and we are pleased to bring such a well-rounded leader on board.”

Princen brings more than 25 years of pharma industry experience to the role, including positions in commercial, marketing, business development and management around the world.

Most recently he served as president of the mid-Europe region at Merck & Co and prior to that, held the role of president and general manager of diversified brands.

Princen succeeds Trevor Smith, who will now work in the UK after commuting to Zurich for several years. Smith stepped down on November 1 and will aid the transition of leadership until his departure from Takeda on March 31, 2015.

26th November 2014

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Wave Healthcare Communications

Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...

Latest intelligence

Virtual Steering Committee & Peer Influence Program
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
Meeting healthcare’s rising challenges
The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
Report gives insights to address gaps in HCP engagement
How does Pharma-HCP engagement need to evolve in today's digital landscape?...